February 10, 2022 – For the sixth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed℠ electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
As a CMS-approved QCDR, Practice Insights℠, a performance analytics tool powered by Ontada®, can collect and report clinical data on behalf of clinicians for both MIPS and custom QCDR quality measures to drive improvements in quality and cost of care.
Seven custom QCDR measures identified by physician leaders in The US Oncology Network and submitted by McKesson were approved by CMS. These include:
- COVID-19 vaccinations (NEW for 2022)
- Advance care planning in metastatic cancer patients
- Hepatitis B serology testing and prophylactic treatment prior to receiving anti-CD20 targeting drugs
- Mutation testing for lung cancer completed prior to start of targeted therapy
- Patient-reported pain improvement
- Supportive care drug utilization in last 14 days of life
- Utilization of granulocyte colony-stimulation factors (GCSF) in metastatic colorectal cancer